Expanded Range of up to -7.00D Makes Myopia Control
a Possibility for More Children Than Ever Before
SAN RAMON, CALIF., June 16, 2022—CooperVision today announced that its MiSight® 1 day contact lenses will be available in higher prescriptions, beginning June 2022. The expanded range—covering -0.50D to -7.00D (0.50D steps after -6.00D) in the U.S.— covers nearly 100% of spherical prescriptions for age-appropriate children* (who were initially fit between ages 8-12) with myopia.1‡ The two new powers for this innovative, specially designed lens will allow even more children to benefit from myopia control.
With myopia on the rise globally,2 an increasing number of age-appropriate* children may require the higher prescriptions that MiSight® 1 day lenses will offer.
“A greater range of MiSight® 1 day powers is excellent news for my practice and patients,” said Charles Morgan, MD, of Advocare Pediatric Eye Physicians in Morristown, NJ. “We have age-appropriate* patients with higher levels of myopia who will now be able to access MiSight’s proven myopia control benefits.”3†
The expanded range will be included in CooperVision’s OptiExpert™ Contact Lens Calculator, an app-based tool that helps eye care professionals by calculating back vertex distance and displaying the closest power-matched MiSight® 1 day prescription for a patient.
As a global leader in myopia management for children, CooperVision believes that options must be available for as many children as possible. With MiSight® 1 day’s range extension, eye care professionals in the U.S. and in more than 30 other countries can have even greater impact.
“Every diopter matters, particularly for children whose myopia progression may have already placed them at a higher risk for conditions such as myopic maculopathy and glaucoma,”4 said Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision. “While early treatment is best, it’s never too late to start.”
# # #
*Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
‡Includes prescriptions up to 0.75DC
†Compared to a single vision 1 day lens over a 3-year period.
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Hannah Barry, Counselor, McDougall Communications
firstname.lastname@example.org or +1-585-645-8985
1 CVI Data on file, 2022. SERE coverage of childhood myopia prescriptions with MiSight® 1 day for 104,810 eyes in Asia (China, Korea) and 116,336 eyes in Europe and USA aged 8-18 years.
2 Holden et al, Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-1042.
3 Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci. 2019; 96(8)556-567.
4 Bullimore et al. Myopia Control: Why Each Diopter Matters Optom Vis Sci 2019;96:463–465.